HL Genomics Co Ltd
0156T0
Company Profile
Business description
HL Genomics Co Ltd is engaged in the business of research and development, manufacturing, processing, storage, and distribution of pharmaceuticals. The group possesses specialized technological capabilities and portfolios in specific therapeutic areas-such as the cardiovascular, respiratory, digestive, and neurological systems-where demand is continuously expanding due to the aging population and the rise in chronic diseases.
Contact
1552, Bogaewonsam-ro
Wonsam-myeon
Cheoin-gu, Gyeonggi-do
Yongin-si
KORT: +82 313352080
Sector
Healthcare
Stock type
Defensive
Industry
Pharmaceutical Retailers
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
Wide moat share expects luck to turn
A tough year for jackpots however earnings are expected to normalise.
stocks
ASX share’s growth story intact despite supply constraints
Short term supply challenges but Chinese growth story remains intact.
stocks
ASX healthcare giant rallies despite a fall in profits
Easing investor concerns and signalling a return to growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,269.70 | 13.70 | -0.15% |
| CAC 40 | 8,453.31 | 0.22 | 0.00% |
| DAX 40 | 26,019.39 | 36.35 | 0.14% |
| Dow JONES (US) | 52,759.21 | 703.84 | -1.32% |
| FTSE 100 | 10,752.80 | 4.64 | 0.04% |
| HKSE | 26,009.46 | 310.97 | 1.21% |
| NASDAQ | 26,067.17 | 263.92 | -1.00% |
| Nikkei 225 | 66,016.36 | 200.43 | -0.30% |
| NZX 50 Index | 13,972.66 | 52.84 | 0.38% |
| S&P 500 | 7,641.16 | 66.82 | -0.87% |
| S&P/ASX 200 | 9,058.90 | 6.90 | -0.08% |
| SSE Composite Index | 3,905.20 | 1.48 | 0.04% |